±Ç¿À¿õ ¸íÀÇ

Àü ´ëÇѾȰúÇÐȸÀå, ¸Á¸· ºÐ¾ß ±ÇÀ§ÀÚ,anti-VEGF ¾à¹° ÁÖ»ç Ä¡·á ±¹³» ÃÖÃÊ µµÀÔ

±Ç¿À¿õ ¸íÀÇ

  • ¼Ò ¼Ó
    ´©³×¾È°úº´¿ø ¾È°ú
  • Àü¹®ºÐ¾ß
    ¸Á¸·, Æ÷µµ¸·, ¹é³»Àå

¾È°úÇÐȸÀåÀÌÀÚ ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¸í¿¹±³¼öÀÌ´Ù. ¿¬¼¼´ë ¼¼ºê¶õ½º ¾È¡¤À̺ñÀÎÈİúº´¿øÀå°ú ¼¼°èȲ¹ÝÇÐȸ ±¹Á¦À§¿øÀå, Çö ´©³×¾È°úº´¿øÀåÀ» ¿ªÀÓÇß´Ù.
ƯÈ÷ ´ç´¢¸Á¸·º´Áõ Ä¡·á ºÐ¾ß¿¡ ¡®±¤¹üÀ§ ¸Á¸·Áõ½Ä Á¦°Å¼ú¡¯°ú Ȳ¹Ýº¯¼ºÀ¸·Î »õ·Î ¸¸µé¾îÁø Ç÷°üÁ¶Á÷À» ã¾Æ ¾ø¾Ö´Â ±¤¿ªÇÐ Ä¡·á ¹× Ç×ü ÁÖ»ç Ä¡·á¸¦ ±¹³» ÃÖÃÊ ½ÃµµÇßÀ¸¸ç, ºÒÄ¡º´À¸·Î ¾Ë·ÁÁø Á¤¸ÆÇ÷°üÆó¼âÁõ Ä¡·á¿¡ ¡®Ç÷Àü¿ëÇØÁ¦ Á÷Á¢ ÁÖÀÔ¼ú¡¯À» ¾Æ½Ã¾Æ ÃÖÃÊ·Î ½ÃÇàÇÏ´Â µî ¾È°úÇÐ ¹ßÀü¿¡ ¸¹Àº ³ë·ÂÀ» ÇÏ´Â ¸íÀÇ·Î ¾Ë·ÁÁ® ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ Á¹¾÷
  • ¿¬¼¼´ëÇб³ ´ëÇпø ÀÇÇйڻç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ´©³×¾È°úº´¿ø ¼­¿ï º´¿øÀå
  • úÞ) ´©³×¾È°úº´¿ø ³²¾çÁÖ ¿øÀå
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¸í¿¹±³¼ö
  • ¹Ì±¹ ¿ÀÇÏÀÌ¿ÀÁÖ¸³´ë ¾È°ú ¿¬±¸¿ø
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ±³¼ö
  • ¿¬¼¼´ëÇб³ ÀÇ·á¿ø ¼¼ºê¶õ½ºº´¿ø ¾È°ú °úÀå
  • ¿¬¼¼´ëÇб³ ±³¼öÆòÀÇȸ ÀÇÀå
  • ¿¬¼¼´ëÇб³ ÀÇ·á¿ø ¾È¡¤À̺ñÀÎÈİú º´¿øÀå (6´ë)

¼ö»ó³»¿ª

Awards List
  • ¾È°úÇÐȸ Çѱæ¾È°ú Çмú»ó 2010
  • ¸Á¸·ÇÐȸ Çмú»ó 2006
  • ¼¼ºê¶õ½ºº´¿ø ¿ì¼ö ¾÷Àû»ó 2001, APAO

ÇÐȸȰµ¿

Academic activities
  • 1987 ~ Çѱ¹¸Á¸·ÇÐȸ 7ÀΠ⸳ À§¿ø
  • 1990 ~ 1992´ëÇѾȰúÇÐȸ ÇмúÁö ÆíÁýÀ§¿øÀå
  • 2007 ~ 2021¾ÆÅ¸Á¸·ÇÐȸ ⸳ ¹× ¿î¿µÀÌ»ç
  • 2011 ~ 2012´ëÇѾȰúÇÐȸ ȸÀå
  • 2013 ~ 2015¼¼°èȲ¹ÝÇÐȸ ±¹Á¦À§¿øÀå
  • ¹Ì±¹ ¸Á¸·ÇÐȸ, ¹Ì±¹ Ȳ¹ÝÇÐȸ, À¯·´ ¸Á¸·ÇÐȸ Á¤È¸¿ø
  • ´ëÇѾȰúÇÐȸ Á¤È¸¿ø
  • Çѱ¹¸Á¸·ÇÐȸ ȸÀå
Ȳ¹Ý
´ëÇ¥¼­Àû

Ȳ¹Ý

  • ÀúÀÚ(±Û)±Ç¿À¿õ À¯È£¹Î À̼ºÃ¶
  • ÃâÆÇ»çµµ¼­ÃâÆÇ Áø±âȹ
  • ¹ßÇàÀÏ2015-12-15
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 1°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*): A 12-month, randomized, controlled, double-masked, multicenter phase II study.
¹ßÇ¥³âµµ 2010 ¹ßÇ¥Áö Diabetes Care
Á¦ ¸ñ Concentration of Cytokines in the Aqueous Humor of Patients with Naïve, Recurrent and Regressed CNV associated with AMD after Bevacizumab Treatment
¹ßÇ¥³âµµ 2009 ¹ßÇ¥Áö Retina
Á¦ ¸ñ Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy.
¹ßÇ¥³âµµ 2009 ¹ßÇ¥Áö Ophthalmologica
Á¦ ¸ñ Estimated Prevalence and Risk Factor for Age-related Maculopathy.
¹ßÇ¥³âµµ 2008 ¹ßÇ¥Áö Yonsei Med J
Á¦ ¸ñ Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.
¹ßÇ¥³âµµ 2008 ¹ßÇ¥Áö Jpn J Ophthalmol
Á¦ ¸ñ Polypoidal Choroidal Vasculopathy in Korean Patients with Large Submacular Hemorrhage
¹ßÇ¥³âµµ 2007 ¹ßÇ¥Áö Yonsei Med J
Á¦ ¸ñ Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.
¹ßÇ¥³âµµ 2004 ¹ßÇ¥Áö Ophthalmologica

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

[ºÐ¾ß] ¿¬·É°ü·ÃȲ¹Ýº¯¼º
[¾÷Àû] 2006 ¸Á¸·ÇÐȸ Çмú»ó ¼ö»ó 2010 Çѱ¹¾È°úÇÐȸ Çѱæ Çмú»ó ¼ö»ó

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

¾ÈÀüÇϰí Áø½ÇµÈ Áø·á. ȯÀÚ¸¦ Á¸ÁßÇÏ´Â ¸¶À½

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

ÀηùÀÇ »ýÁ¸ ¿¬·ÉÀÌ Á¡Â÷ ´Ã¾î³ª°í °æÁ¦ÀûÀ¸·Î ¹ß´ÞÇÔ¿¡ µû¶ó ÀÏ»ó »ýȰÀ» ºñ·ÔÇÏ¿© ¸ð´ø Ȱµ¿ ¿µ¿ª¿¡¼­ ½Ã·ÂÀÇ Á߿伺Àº Á¡Á¡ ³ô¾ÆÁö°í ÀÖ´Ù.
¼¼°èÀûÀÎ Ãß¼¼¸¦ º¸¸é ¾È°ú ºÐ¾ßÀÇ ¼öÁØÀº ±Þ¼ºÀåÀ» ÇßÀ¸³ª ¾ÆÁ÷ ºÎÁ·ÇÑ ºÎºÐ ÁßÀÇ ÇϳªÀÎ ½À¼ºÈ²¹Ýº¯¼º°ú ´ç´¢È²¹ÝºÎÁ¾ µîÀÌ ³­Ä¡º´À¸·Î ¹®Á¦°¡ µÇ°í ÀÖ´Ù. ½À¼ºÈ²¹Ýº¯¼º°ú ´ç´¢È²¹ÝºÎÁ¾Àº Ä¡·á ½Ã±â¸¦ ³õÄ¡¸é ±× ÈÄ¿¡ ¾Æ¹«¸® Àß Ä¡·á¸¦ ÇÏ¿©µµ ½Ã·Â ¼Õ»óÀ» ȸº¹ÇÏ±â ¾î·Æ´Ù. ¾È±¸³» anti-VEGFÁ¦Á¦´Â ÃÖ±Ù ±¹³»¿Ü¿¡¼­ »õ·Î¿î Á¦Ç°µéÀÌ ¿©·µ Ãâ½ÃµÇ¾î Ȱ¹ßÇÏ°Ô ¾²À̰í ÀÖÀ¸¸ç ±× È¿°ú´Â ºñ±³Àû ÁÁÀº ÆíÀÌÁö¸¸ 1-3´Þ¸¶´Ù ¿©·¯¹ø ¹øº¹ Åõ¿©¸¦ °è¼Ó ÇØ¾ßÇÏ´Â ¾î·Á¿òÀÌ ³²¾Æ ÀÖ´Ù. ÃÖ±Ù Çѹø ÁÖ»ç Åõ¿©·Î Àå±â°£ È¿°ú¸¦ º¼ ¼ö ÀÖ´Â ¾àÁ¦ÀÇ ÃâÇöÀÌ ¿¹°ßµÇ°í ¾È±¸³»Áֻ簡 ¾Æ´Ñ °æ±¸Åõ¿©·Î Ä¡·á°¡ °¡´ÉÇÑ Â÷¼¼´ë ¾àÁ¦ °³¹ß¿¡ ÁýÁßÇϰí ÀÖÀ¸¹Ç·Î ÀæÀº ¾È±¸³»ÁÖ»ç Ä¡·áÀÇ ¾î·Á¿ò¿¡¼­ ÇØ¹æµÇ´Â ½Ã±â°¡ °ð ¿Ã °ÍÀ¸·Î ±â´ëÇÑ´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

´©³×¾È°úº´¿ø

Àü¹®º´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
031-522-4266
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

´©³×¾È°úº´¿øÀº ¸íÀǸ¦ ºñ·Ô, ¿ì¼öÇÑ ÀÇ·áÁø°ú ÷´Ü ½Ã¼³À» °®Ãß°í ÀÖ¾î °¢¸·, ¸Á¸·, ¹é³»Àå, ³ì³»Àå, »ç½Ã, ½Ã·Â±³Á¤, ¾È¼ºÇü µî ´«¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Â ¸ðµç ÁúȯÀ» ÇÑ °÷¿¡¼­ Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ³²¾çÁÖ ´©³×¾È°úº´¿øÀº ±âº» °Ë»ç½Ç ¹× Á¤¹Ð °Ë»ç½Ç, °ÇÁ¶ÁõŬ¸®´Ð, óġ½Ç, ÁÖ»ç½ÇÀº ¹°·Ð ·»Áî½Ç, ¼ö¼ú¼¾ÅÍ, º´µ¿±îÁö °®Ãß°í ÀÖ¾î ü°èÀûÀ¸·Î Áø·á¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.

´©³×¾È°úº´¿ø À̹ÌÁö

°æ±âµµ ³²¾çÁÖ½Ã ÇØ¹Ð¿¹´ç1·Î 28 ÁøÁ¢³óÇù 4Ãþ

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä